Literature DB >> 18089837

N-(6-chloro-pyridin-3-yl)-3,4-difluoro-benzamide (ICA-27243): a novel, selective KCNQ2/Q3 potassium channel activator.

A D Wickenden1, J L Krajewski, B London, P K Wagoner, W A Wilson, S Clark, R Roeloffs, G McNaughton-Smith, G C Rigdon.   

Abstract

KCNQ2 (Kv7.2) and KCNQ3 (Kv7.3) are voltage-gated K(+) channel subunits that underlie the neuronal M current. In humans, mutations in these genes lead to a rare form of neonatal epilepsy (Biervert et al., 1998; Singh et al., 1998), suggesting that KCNQ2/Q3 channels may be attractive targets for novel antiepileptic drugs. In the present study, we have identified the compound N-(6-chloro-pyridin-3-yl)-3,4-difluoro-benzamide (ICA-27243) as a selective activator of the neuronal M current and KCNQ2/Q3 channels. In SH-SY5Y human neuroblastoma cells, ICA-27243 produced membrane potential hyperpolarization that could be prevented by coadministration with the M-current inhibitors 10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone dihydrochloride (XE-991) and linopirdine. ICA-27243 enhanced both (86)Rb(+) efflux (EC(50) = 0.2 microM) and whole-cell currents in Chinese hamster ovary cells stably expressing heteromultimeric KCNQ2/Q3 channels (EC(50) = 0.4 microM). Activation of KCNQ2/Q3 channels was associated with a hyperpolarizing shift of the voltage dependence of channel activation (V((1/2)) shift of -19 mV at 10 microM). In contrast, ICA-27243 was less effective at activating KCNQ4 and KCNQ3/Q5 and was selective over a wide range of neurotransmitter receptors and ion channels such as voltage-dependent sodium channels and GABA-gated chloride channels. ICA-27243 (1-10 microM) was found to reversibly suppress seizure-like activity in an ex vivo hippocampal slice model of epilepsy and demonstrated in vivo anticonvulsant activity (ED(50) = 8.4 mg/kg) in the mouse maximal electroshock epilepsy model. In conclusion, ICA-27243 represents the first member of a novel chemical class of selective KCNQ2/Q3 activators with anticonvulsant-like activity in experimental models of epilepsy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18089837     DOI: 10.1124/mol.107.043216

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  51 in total

1.  Overview of drugs used for epilepsy and seizures: etiology, diagnosis, and treatment.

Authors:  Marvin M Goldenberg
Journal:  P T       Date:  2010-07

2.  Novel KCNQ2 channel activators discovered using fluorescence-based and automated patch-clamp-based high-throughput screening techniques.

Authors:  Jin-feng Yue; Guan-hua Qiao; Ni Liu; Fa-jun Nan; Zhao-bing Gao
Journal:  Acta Pharmacol Sin       Date:  2016-01       Impact factor: 6.150

3.  Diclofenac distinguishes among homomeric and heteromeric potassium channels composed of KCNQ4 and KCNQ5 subunits.

Authors:  Lioubov I Brueggemann; Alexander R Mackie; Jody L Martin; Leanne L Cribbs; Kenneth L Byron
Journal:  Mol Pharmacol       Date:  2010-09-28       Impact factor: 4.436

4.  Phosphatidylinositol 4,5-bisphosphate alters pharmacological selectivity for epilepsy-causing KCNQ potassium channels.

Authors:  Pingzheng Zhou; Haibo Yu; Min Gu; Fa-jun Nan; Zhaobing Gao; Min Li
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-06       Impact factor: 11.205

Review 5.  Ion channels as drug targets in central nervous system disorders.

Authors:  A M Waszkielewicz; A Gunia; N Szkaradek; K Słoczyńska; S Krupińska; H Marona
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

6.  The riluzole derivative 2-amino-6-trifluoromethylthio-benzothiazole (SKA-19), a mixed KCa2 activator and NaV blocker, is a potent novel anticonvulsant.

Authors:  Nichole Coleman; Hai M Nguyen; Zhengyu Cao; Brandon M Brown; David Paul Jenkins; Dorota Zolkowska; Yi-Je Chen; Brian S Tanaka; Alan L Goldin; Michael A Rogawski; Isaac N Pessah; Heike Wulff
Journal:  Neurotherapeutics       Date:  2015-01       Impact factor: 7.620

Review 7.  Neural KCNQ (Kv7) channels.

Authors:  David A Brown; Gayle M Passmore
Journal:  Br J Pharmacol       Date:  2009-03-09       Impact factor: 8.739

8.  Orchestration of "presto" and "largo" synchrony in up-down activity of cortical networks.

Authors:  Francesca Gullo; Samanta Mazzetti; Andrea Maffezzoli; Elena Dossi; Marzia Lecchi; Alida Amadeo; Jeffrey Krajewski; Enzo Wanke
Journal:  Front Neural Circuits       Date:  2010-04-22       Impact factor: 3.492

Review 9.  Voltage-gated potassium channels as therapeutic targets.

Authors:  Heike Wulff; Neil A Castle; Luis A Pardo
Journal:  Nat Rev Drug Discov       Date:  2009-12       Impact factor: 84.694

Review 10.  One man's side effect is another man's therapeutic opportunity: targeting Kv7 channels in smooth muscle disorders.

Authors:  T A Jepps; S P Olesen; I A Greenwood
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.